Rheumatology

Your Article Summary

See Latest Articles

An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis
Amyloid The Journal of Protein Folding Disorders, 11/01/07

Sanchorawala, V., et al. - AL amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. This review outlines an overview of high-dose intravenous melphalan and stem cell transplantation in the treatment of AL amyloidosis. An algorithm of our recommendations for the treatment of AL amyloidosis is also outlined

Today in Amyloidosis...keeping you current

Receive free subspecialty "5-minute updates" via email

Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis
Annals of Hematology, 12/18/09

Clinical features and functional significance of the P369S/ R408Q variant in pyrin, the familial Mediterranean fever protein
Annals of Rheumatic Diseases, 12/11/09

MEFV mutations in Egyptian patients suffering from familial Mediterranean fever: analysis of 12 gene mutations
Rheumatology International, 10/16/09

 See all of Amyloidosis

Today in Clinical Pharmacology...keeping you current

Receive free subspecialty "5-minute updates" via email

Malignancy-associated multicentric reticulohistiocytosis
Rheumatology International, 12/20/09

Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil
Rheumatology, 12/18/09

Nicotine-patch therapy on mucocutaneous lesions of Behcet's disease: A case series
Rheumatology, 12/18/09

 See all of Clinical Pharmacology